You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 8,354,437


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,354,437
Title:Method of using sustained release aminopyridine compositions
Abstract: A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at about 12 hours and the use of the composition to treat various neurological diseases, including multiple sclerosis. A method of selecting individuals based on responsiveness to a treatment, including, for example, identifying individuals who responded to treatment with a sustained release fampridine composition.
Inventor(s): Blight; Andrew R. (Mahopac, NY), Cohen; Ron (Irvington, NY)
Assignee: Acorda Therapeutics, Inc. (Ardsley, NY)
Application Number:11/102,559
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,354,437
Patent Claims: 1. A method of increasing walking speed in a human multiple sclerosis patient in need thereof comprising orally administering to said patient a sustained release composition of 10 milligrams of 4-aminopyridine twice daily for a time period of at least two weeks, wherein said 10 milligrams of 4-aminopyridine twice daily are the only doses of 4-aminopyridine administered to said patient during said time period.

2. A method of improving walking in a human multiple sclerosis patient in need thereof comprising orally administering to said patient a sustained release composition of 10 milligrams of 4-aminopyridine twice daily for a time period of at least two weeks, wherein said 10 milligrams of 4-aminopyridine twice daily are the only doses of 4-aminopyridine administered to said patient during said time period.

3. A method of improving lower extremity muscle tone in a human multiple sclerosis patient in need thereof comprising orally administering to said patient a sustained release composition of 10 milligrams of 4-aminopyridine twice daily for a time period of at least two weeks, wherein said 10 milligrams of 4-aminopyridine twice daily are the only doses of 4-aminopyridine administered to said patient during said time period.

4. A method of improving lower extremity muscle strength in a human multiple sclerosis patient in need thereof comprising orally administering to said patient a sustained release composition of 10 milligrams of 4-aminopyridine twice daily for a time period of at least two weeks, wherein said 10 milligrams of 4-aminopyridine twice daily are the only doses of 4-aminopyridine administered to said patient during said time period.

5. The method of claim 1 wherein said time period comprises twelve weeks.

6. The method of claim 2 wherein said time period comprises twelve weeks.

7. The method of claim 3 wherein said time period comprises twelve weeks.

8. The method of claim 4 wherein said time period comprises twelve weeks.

9. The method of claim 1 wherein said method comprises initiating treatment of said patient with 4-aminopyridine by orally administering said sustained release composition twice daily to said patient.

10. The method of claim 2 wherein said method comprises initiating treatment of said patient with 4-aminopyridine by orally administering said sustained release composition twice daily to said patient.

11. The method of claim 3 wherein said method comprises initiating treatment of said patient with 4-aminopyridine by orally administering said sustained release composition twice daily to said patient.

12. The method of claim 4 wherein said method comprises initiating treatment of said patient with 4-aminopyridine by orally administering said sustained release composition twice daily to said patient.

13. The method of claim 1 wherein twice daily is about every 12 hours.

14. The method of claim 2 wherein twice daily is about every 12 hours.

15. The method of claim 3 wherein twice daily is about every 12 hours.

16. The method of claim 4 wherein twice daily is about every 12 hours.

17. The method of claim 5 wherein twice daily is about every 12 hours.

18. The method of claim 1 wherein said sustained release composition is a tablet.

19. The method of claim 2 wherein said sustained release composition is a tablet.

20. The method of claim 3 wherein said sustained release composition is a tablet.

21. The method of claim 4 wherein said sustained release composition is a tablet.

22. The method of claim 18 wherein said tablet exhibits a release profile to obtain a C.sub.avSS of about 15 ng/ml to about 35 ng/ml.

23. The method of claim 19 wherein said tablet exhibits a release profile to obtain a .sub.CavSS of about 15 ng/ml to about 35 ng/ml.

24. The method of claim 20 wherein said tablet exhibits a release profile to obtain a C.sub.avSS of about 15 ng/ml to about 35 ng/ml.

25. The method of claim 21 wherein said tablet exhibits a release profile to obtain a C.sub.avSS of about 15 ng/ml to about 35 ng/ml.

26. The method of claim 1 further comprising a step of measuring walking speed of the patient.

27. The method of claim 4 further comprising a step of measuring lower extremity muscle strength of the patient.

28. The method of claim 1 wherein said patient has relapsing remitting multiple sclerosis.

29. The method of claim 2 wherein said patient has relapsing remitting multiple sclerosis.

30. The method of claim 3 wherein said patient has relapsing remitting multiple sclerosis.

31. The method of claim 4 wherein said patient has relapsing remitting multiple sclerosis.

32. A method of increasing walking speed in a human multiple sclerosis patient in need thereof comprising orally administering to said patient a sustained release tablet of 10 milligrams of 4-aminopyridine at about every 12 hours for a time period of at least two weeks, wherein said 10 milligrams of 4-aminopyridine at about every 12 hours are the only doses of 4-aminopyridine administered to said patient during said time period.

33. A method of improving walking in a human multiple sclerosis patient in need thereof comprising orally administering to said patient a sustained release tablet of 10 milligrams of 4-aminopyridine at about every 12 hours for a time period of at least two weeks, wherein said 10 milligrams of 4-aminopyridine at about every 12 hours are the only doses of 4-aminopyridine administered to said patient during said time period.

34. A method of improving lower extremity muscle tone in a human multiple sclerosis patient in need thereof comprising orally administering to said patient a sustained release tablet of 10 milligrams of 4-aminopyridine at about every 12 hours for a time period of at least two weeks, wherein said 10 milligrams of 4-aminopyridine at about every 12 hours are the only doses of 4-aminopyridine administered to said patient during said time period.

35. A method of improving lower extremity muscle strength in a human multiple sclerosis patient in need thereof comprising orally administering to said patient a sustained release tablet of 10 milligrams of 4-aminopyridine at about every 12 hours for a time period of at least two weeks, wherein said 10 milligrams of 4-aminopyridine at about every 12 hours are the only doses of 4-aminopyridine administered to said patient during said time period.

36. The method of claim 32 wherein said time period comprises twelve weeks.

37. The method of claim 33 wherein said time period comprises twelve weeks.

38. A method of treating walking disability in a human multiple sclerosis patient in need thereof comprising orally administering to said patient a sustained release composition of 10 milligrams of 4-aminopyridine twice daily for a time period of at least two weeks, wherein said 10 milligrams of 4-aminopyridine twice daily are the only doses of 4-aminopyridine administered to said patient during said time period.

39. The method of claim 38 wherein said method comprises orally administering to said patient a sustained release tablet of 10 milligrams of 4-aminopyridine at about every 12 hours for a time period of at least two weeks.

40. The method of claim 39 wherein said time period comprises 12 weeks.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.